Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebipenem PK in Diabetic Lower Limb Infections
NCT04919954Phase 1Completed
- Sponsor
- Hartford Hospital
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of tebipenem in Wound infection (WI) and acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Hartford Hospital. Primary endpoint: Tebipenem Pivoxil Hydrobromide Tissue Penetration at 8 hours. Started Jul 2021; status: completed.
02
Drugs
tebipenem
03
Conditions
Wound infection (WI)acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT04919954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919954.